ANDA 205519, held by Sciegen Pharms. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 205519 (Atorvastatin Calcium), held by Sciegen Pharms, was first approved by FDA on May 19, 2016, with 12 approved supplements and 0 published complete response letters.
Atorvastatin Calcium Tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 19, 2016 | Original application | Approved |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Apr 28, 2026 | Supplement 43Labeling · Standard review | Approved | None posted |
| Jan 22, 2026 | Supplement 44Manufacturing | Approved | None posted |
| Mar 8, 2023 | Supplement 34Labeling · Standard review | Approved | None posted |
| Oct 25, 2022 | Supplement 28Labeling · Standard review | Approved | None posted |
| May 27, 2021 | Supplement 25Labeling · Standard review | Approved | None posted |
| May 27, 2021 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jul 1, 2020 | Supplement 21Labeling · Standard review | Approved | None posted |
| Oct 21, 2019 | Supplement 18Labeling · Standard review | Approved | None posted |
| Oct 21, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 21, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 21, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 21, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 19, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters